Research programme: anti-tau antibodies - AC Immune/Genentech
Latest Information Update: 04 Nov 2017
At a glance
- Originator AC Immune
- Developer AC Immune; Genentech
- Class Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Switzerland (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Switzerland (Parenteral)
- 09 Jan 2014 Preclinical development is ongoing